M Pinto1, R E Steffen2, F Cobelens3, S van den Hof3, A Entringer1, A Trajman4. 1. Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. 2. Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil. 3. KNCV Tuberculosis Foundation, The Hague, The Netherlands; Department of Global Health, Academic Medical Center, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands. 4. Rio de Janeiro Federal University, Rio de Janeiro, Rio de Janeiro, Brazil, McGill University, Montréal, Quebec, Canada.
Abstract
INTRODUCTION: The Xpert® MTB/RIF assay is being implemented as a substitute for sputum smear microscopy (SSM) in many low and high tuberculosis (TB) burden countries, including Brazil, a country with low multidrug resistance and moderate human immunodeficiency virus co-infection rates. SETTING: Brazilian National TB Programme (NTP). OBJECTIVE AND DESIGN: We estimated the incremental cost-effectiveness ratio (ICER) of Xpert as a substitute for two SSM tests in the diagnosis of drug-susceptible TB. The costs for confirming each additional case and for avoiding treatment due to false-positive empirical diagnoses were estimated. RESULTS: The ICER was US$943 for each additional TB diagnosis and US$356 for each additional TB diagnosis with bacteriological confirmation, assuming 80% specificity of clinical diagnosis using both strategies. For every 100 000 patients with suspected TB, the NTP would spend an additional US$1.2 million per year to confirm 3344 more TB patients. The model was highly sensitive to specificity of clinical diagnosis after a negative test. CONCLUSION: Although the NTP has no threshold for cost-effectiveness, our model can provide support for decision makers in Brazil and other countries with a low prevalence of drug resistance among TB patients. Financial benefit can potentially be expected if physicians rely more on a negative Xpert result and empirical treatment is reduced.
INTRODUCTION: The Xpert® MTB/RIF assay is being implemented as a substitute for sputum smear microscopy (SSM) in many low and high tuberculosis (TB) burden countries, including Brazil, a country with low multidrug resistance and moderate human immunodeficiency virus co-infection rates. SETTING: Brazilian National TB Programme (NTP). OBJECTIVE AND DESIGN: We estimated the incremental cost-effectiveness ratio (ICER) of Xpert as a substitute for two SSM tests in the diagnosis of drug-susceptible TB. The costs for confirming each additional case and for avoiding treatment due to false-positive empirical diagnoses were estimated. RESULTS: The ICER was US$943 for each additional TB diagnosis and US$356 for each additional TB diagnosis with bacteriological confirmation, assuming 80% specificity of clinical diagnosis using both strategies. For every 100 000 patients with suspected TB, the NTP would spend an additional US$1.2 million per year to confirm 3344 more TB patients. The model was highly sensitive to specificity of clinical diagnosis after a negative test. CONCLUSION: Although the NTP has no threshold for cost-effectiveness, our model can provide support for decision makers in Brazil and other countries with a low prevalence of drug resistance among TB patients. Financial benefit can potentially be expected if physicians rely more on a negative Xpert result and empirical treatment is reduced.
Authors: Anil Pooran; Grant Theron; Lynn Zijenah; Duncan Chanda; Petra Clowes; Lawrence Mwenge; Farirai Mutenherwa; Paul Lecesse; John Metcalfe; Hojoon Sohn; Michael Hoelscher; Alex Pym; Jonny Peter; David Dowdy; Keertan Dheda Journal: Lancet Glob Health Date: 2019-06 Impact factor: 26.763
Authors: E N Bogdanova; A O Mariandyshev; G A Balantcev; P I Eliseev; E I Nikishova; A I Gaida; D Enarson; A Detjen; R Dacombe; P P J Phillips; S B Squire; E Gospodarevskaya Journal: PLoS One Date: 2019-01-29 Impact factor: 3.240
Authors: Cinara Silva Feliciano; Lucas José Bazzo Menon; Livia Maria Pala Anselmo; Anzaan Dippenaar; Robin Mark Warren; Wilson Araújo Silva; Valdes Roberto Bollela Journal: ERJ Open Res Date: 2019-08-05
Authors: Luiza M Neves; Lorena M Haefeli; Andrea A Zin; Ricardo E Steffen; Zilton F M Vasconcelos; Márcia Pinto Journal: Front Pediatr Date: 2021-12-16 Impact factor: 3.418
Authors: Simon van der Pol; Paula Rojas Garcia; Maarten J Postma; Fernando Antoñanzas Villar; Antoinette D I van Asselt Journal: Pharmacoeconomics Date: 2021-07-15 Impact factor: 4.981